febit Launches Whole Genome Sequencing Service in Europe
News Mar 23, 2010
febit has announced that the company now offers whole genome sequencing services in Europe for a broad range of species. febit is known for its targeted resequencing services and instruments for genome exploration.
febit has acquired two Applied Biosystems SOLiD™ high-throughput sequencing systems from Life Technologies Corporation, necessary for whole genome resequencing. One of the two systems will be used within R&D while the other is employed within febit’s Genomic Service Department. Life Technologies is a global biotechnology tools company providing premier systems, consumables, and services for scientific researchers around the world.
“We combine our expertise in optimizing samples for highest coverage in targeted resequencing with the established SOLiD sequencing power,” said Peer Staehler, CSO of febit. “This will enable us to offer whole genome sequencing at very competitive prices; the price for resequencing a whole human genome will start at 9,750 Euro. The ultra-deep resequencing with 99.94 % accuracy allows confident SNP and mutation detection as well as the detection of structural variations such as insertions, deletions, inversions and translocations.”
The new whole genome resequencing service extends febit’s service portfolio which is already well established for targeted resequencing of genomic regions of interest with its high throughput HybSelect-technology. Together with a barcoding option, febit’s new service portfolio will advance the use of next-generation sequencing for larger scale clinical studies due to effective costs and data management.
New Inherited Neurodevelopmental Disease DiscoveredNews
Researchers have identified a new inherited neurodevelopmental disease that causes slow growth, seizures and learning difficulties in humans.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE